HGS Lymphostat-B Is 1 Of 7 Agents Selected For FDA’s Pilot 2 CMA Program
This article was originally published in Pharmaceutical Approvals Monthly
FDA has selected Human Genome Sciences’ lupus biologic Lymphostat-B for the continuous marketing application (CMA) Pilot 2 program, HGS announced March 4.
You may also be interested in...
FDA extends continuous marketing application Pilot 2 deadline again. At least eight CDER divisions have chosen INDs for the fast-track pilot program, with eight remaining. Applications will be accepted until Dec. 31